6.27 -0.13 (-2.02%)
AMRI
Stock Details
Last Trade:6.27 Change:-0.13 (-2.02%) Prev Close:6.40 Open: 6.43 Days Range:6.25 – 6.43 52 Week Range: 5.06 - 9.73 Volume:48199 P/E: N/AEPS:-0.74
View AllRecent Alerts 09/09/10
Recent Alert on 08/04/10 at 7:30am
Albany Molecular (AMRI) Posts Q2 adj.-EPS of $0.06, Tops Views; Guides Q3 and FY10
Albany Molecular (AMRI) Posts Q2 adj.-EPS of $0.06, Tops Views; Guides Q3 and FY10
Albany Molecular Research, Inc. (Nasdaq: AMRI) reports Q2 adjusted EPS of $0.06, 10 cents better than the analyst estimate of ($0.04). Revenue for the quarter was $49.5 million, which compares to the estimate of $48.71 million. Sees Q3 revs of... Read More
Recent Alert on 08/04/10 at 7:30am
Albany Molecular (AMRI) Posts Q2 adj.-EPS of $0.06, Tops Views; Guides Q3 and FY10
Albany Molecular (AMRI) Posts Q2 adj.-EPS of $0.06, Tops Views; Guides Q3 and FY10
Recent Alert on 08/03/10 at 3:59pm
Trading Radar for 08/04: AOL (AOL), PulteGroup (PHM), Transocean (RIG), Career Education (CECO) Report
Trading Radar for 08/04: AOL (AOL), PulteGroup (PHM), Transocean (RIG), Career Education (CECO) Report
Recent Alert on 08/03/10 at 3:59pm
Trading Radar for 08/04: AOL (AOL), PulteGroup (PHM), Transocean (RIG), Career Education (CECO) Report
Trading Radar for 08/04: AOL (AOL), PulteGroup (PHM), Transocean (RIG), Career Education (CECO) Report
Recent Alert on 08/02/10 at 3:43pm
Trading Radar for 08/03: Dow Chemical (DOW), CBS Corp. (CBS), MasterCard (MA), MGM Resorts (MGM) Report
Trading Radar for 08/03: Dow Chemical (DOW), CBS Corp. (CBS), MasterCard (MA), MGM Resorts (MGM) Report
View AllRecent Press Releases
Press Release on 09/07/10 at 8:00am
AMRI CFO to Present at the Rodman & Renshaw Annual Global Investment Conference
AMRI CFO to Present at the Rodman & Renshaw Annual Global Investment Conference
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 06/20/10 at 3:59am
Curis Tumbles on Failure of Cancer Drug Trial: Biotech's Latest Mishaps
Curis Tumbles on Failure of Cancer Drug Trial: Biotech's Latest Mishaps